Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.

<h4>Background</h4>Uncertainty underlies the effectiveness of somatostatin analogues for slowing the progression of polycystic kidney or liver disease.<h4>Methods</h4>Eligible studies included randomized controlled trials (RCTs) evaluating somatostatin analog as therapy for p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tatsuya Suwabe, Francisco J Barrera, Rene Rodriguez-Gutierrez, Yoshifumi Ubara, Marie C Hogan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6f9ca9a7b2574d088b588da4331f0ab4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f9ca9a7b2574d088b588da4331f0ab4
record_format	dspace
spelling	oai:doaj.org-article:6f9ca9a7b2574d088b588da4331f0ab42021-12-02T20:08:00ZSomatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.1932-620310.1371/journal.pone.0257606https://doaj.org/article/6f9ca9a7b2574d088b588da4331f0ab42021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257606https://doaj.org/toc/1932-6203<h4>Background</h4>Uncertainty underlies the effectiveness of somatostatin analogues for slowing the progression of polycystic kidney or liver disease.<h4>Methods</h4>Eligible studies included randomized controlled trials (RCTs) evaluating somatostatin analog as therapy for patients with polycystic kidney disease (PKD) or polycystic liver disease (PLD) compared to placebo or standard therapy. Two reviewers independently screened studies identified from databases (MEDLINE, EMBASE, Cochrane Database), clinical trial registries, and references from pertinent articles and clinical practice guidelines. Outcome measurements were changes in total liver volume (TLV), total kidney volume (TKV), and estimated glomerular filtration rate (eGFR).<h4>Results</h4>Of 264 nonduplicate studies screened, 10 RCTs met the inclusion criteria. The body of evidence provided estimates warranting moderate confidence. Meta-analysis of 7 RCTs including a total of 652 patients showed that somatostatin analogs are associated with a lower %TLV growth rate compared to control (mean difference, -6.37%; 95% CI -7.90 to -4.84, p<0.00001), and with a lower %TKV growth rate compared to control (mean difference, -3.66%; 95% CI -5.35 to -1.97, p<0.0001). However, it was not associated with a difference in eGFR decline (mean difference, -0.96 mL/min./1.73m2; 95% CI -2.38 to 0.46, p = 0.19).<h4>Conclusions</h4>Current body of evidence suggests that somatostatin analogs therapy slows the increase rate of TLV and TKV in patients with PKD or PLD compared to control within a 3-year follow-up period. It does not seem to have an effect on the change in eGFR. Somatostatin analogs therapy can be a promising treatment for ADPKD or ADPLD, and we need to continue to research its effectiveness for ADPKD or ADPLD.Tatsuya SuwabeFrancisco J BarreraRene Rodriguez-GutierrezYoshifumi UbaraMarie C HoganPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257606 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tatsuya Suwabe Francisco J Barrera Rene Rodriguez-Gutierrez Yoshifumi Ubara Marie C Hogan Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
description	<h4>Background</h4>Uncertainty underlies the effectiveness of somatostatin analogues for slowing the progression of polycystic kidney or liver disease.<h4>Methods</h4>Eligible studies included randomized controlled trials (RCTs) evaluating somatostatin analog as therapy for patients with polycystic kidney disease (PKD) or polycystic liver disease (PLD) compared to placebo or standard therapy. Two reviewers independently screened studies identified from databases (MEDLINE, EMBASE, Cochrane Database), clinical trial registries, and references from pertinent articles and clinical practice guidelines. Outcome measurements were changes in total liver volume (TLV), total kidney volume (TKV), and estimated glomerular filtration rate (eGFR).<h4>Results</h4>Of 264 nonduplicate studies screened, 10 RCTs met the inclusion criteria. The body of evidence provided estimates warranting moderate confidence. Meta-analysis of 7 RCTs including a total of 652 patients showed that somatostatin analogs are associated with a lower %TLV growth rate compared to control (mean difference, -6.37%; 95% CI -7.90 to -4.84, p<0.00001), and with a lower %TKV growth rate compared to control (mean difference, -3.66%; 95% CI -5.35 to -1.97, p<0.0001). However, it was not associated with a difference in eGFR decline (mean difference, -0.96 mL/min./1.73m2; 95% CI -2.38 to 0.46, p = 0.19).<h4>Conclusions</h4>Current body of evidence suggests that somatostatin analogs therapy slows the increase rate of TLV and TKV in patients with PKD or PLD compared to control within a 3-year follow-up period. It does not seem to have an effect on the change in eGFR. Somatostatin analogs therapy can be a promising treatment for ADPKD or ADPLD, and we need to continue to research its effectiveness for ADPKD or ADPLD.
format	article
author	Tatsuya Suwabe Francisco J Barrera Rene Rodriguez-Gutierrez Yoshifumi Ubara Marie C Hogan
author_facet	Tatsuya Suwabe Francisco J Barrera Rene Rodriguez-Gutierrez Yoshifumi Ubara Marie C Hogan
author_sort	Tatsuya Suwabe
title	Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
title_short	Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
title_full	Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
title_fullStr	Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
title_full_unstemmed	Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
title_sort	somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: a systematic review and meta-analysis of randomized clinical trials.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/6f9ca9a7b2574d088b588da4331f0ab4
work_keys_str_mv	AT tatsuyasuwabe somatostatinanalogtherapyeffectivenessontheprogressionofpolycystickidneyandliverdiseaseasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT franciscojbarrera somatostatinanalogtherapyeffectivenessontheprogressionofpolycystickidneyandliverdiseaseasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT renerodriguezgutierrez somatostatinanalogtherapyeffectivenessontheprogressionofpolycystickidneyandliverdiseaseasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT yoshifumiubara somatostatinanalogtherapyeffectivenessontheprogressionofpolycystickidneyandliverdiseaseasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT mariechogan somatostatinanalogtherapyeffectivenessontheprogressionofpolycystickidneyandliverdiseaseasystematicreviewandmetaanalysisofrandomizedclinicaltrials
_version_	1718375247618506752

Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.

Ejemplares similares